{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:15:09Z","timestamp":1740107709506,"version":"3.37.3"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,8,4]],"date-time":"2018-08-04T00:00:00Z","timestamp":1533340800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"research funds from the Division of Rheumatology at the University of Alabama at Birmingham","award":["No number"],"award-info":[{"award-number":["No number"]}]},{"name":"resources and use of facilities at the Birmingham VA Medical Center, Birmingham, Alabama, USA","award":["No number"],"award-info":[{"award-number":["No number"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s10067-018-4243-7","type":"journal-article","created":{"date-parts":[[2018,8,4]],"date-time":"2018-08-04T06:34:22Z","timestamp":1533364462000},"page":"2557-2566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Goals of gout treatment: a patient perspective"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3485-0006","authenticated-orcid":false,"given":"Jasvinder A.","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,4]]},"reference":[{"key":"4243_CR1","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK (2011) Prevalence of gout and hyperuricemia in the US general population: the National Health and nutrition examination survey 2007-2008. Arthritis Rheum 63:3136\u20133141","journal-title":"Arthritis Rheum"},{"key":"4243_CR2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s11926-009-0022-4","volume":"11","author":"JA Singh","year":"2009","unstructured":"Singh JA (2009) Quality of life and quality of care for patients with gout. Curr Rheumatol Rep 11:154\u2013160","journal-title":"Curr Rheumatol Rep"},{"key":"4243_CR3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1136\/ard.2008.092619","volume":"68","author":"JA Singh","year":"2009","unstructured":"Singh JA, Hodges JS, Asch SM (2009) Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis 68:1265\u20131270","journal-title":"Ann Rheum Dis"},{"key":"4243_CR4","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/art.22767","volume":"57","author":"JA Singh","year":"2007","unstructured":"Singh JA, Hodges JS, Toscano JP, Asch SM (2007) Quality of care for gout in the US needs improvement. Arthritis Rheum 57:822\u2013829","journal-title":"Arthritis Rheum"},{"key":"4243_CR5","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/rheumatology\/keh679","volume":"44","author":"TR Mikuls","year":"2005","unstructured":"Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG (2005) Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) 44:1038\u20131042","journal-title":"Rheumatology (Oxford)"},{"key":"4243_CR6","doi-asserted-by":"publisher","first-page":"925","DOI":"10.4065\/81.7.925","volume":"81","author":"CA Sarawate","year":"2006","unstructured":"Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, Bakst AW (2006) Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 81:925\u2013934","journal-title":"Mayo Clin Proc"},{"key":"4243_CR7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s11926-010-0154-6","volume":"13","author":"NL Edwards","year":"2011","unstructured":"Edwards NL (2011) Quality of care in patients with gout: why is management suboptimal and what can be done about it? Curr Rheumatol Rep 13:154\u2013159","journal-title":"Curr Rheumatol Rep"},{"key":"4243_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1592\/phco.28.4.437","volume":"28","author":"BA Briesacher","year":"2008","unstructured":"Briesacher BA, Andrade SE, Fouayzi H, Chan KA (2008) Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 28:437\u2013443","journal-title":"Pharmacotherapy"},{"key":"4243_CR9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","volume":"11","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Zhang W, Doherty M (2015) Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 11:649\u2013662","journal-title":"Nat Rev Rheumatol"},{"key":"4243_CR10","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1185\/03007995.2010.533647","volume":"26","author":"RA Brook","year":"2010","unstructured":"Brook RA, Forsythe A, Smeeding JE, Lawrence EN (2010) Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Res Opin 26:2813\u20132821","journal-title":"Curr Med Res Opin"},{"key":"4243_CR11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s11926-996-0043-1","volume":"7","author":"HK Choi","year":"2005","unstructured":"Choi HK (2005) Diet, alcohol, and gout: how do we advise patients given recent developments? Curr Rheumatol Rep 7:220\u2013226","journal-title":"Curr Rheumatol Rep"},{"key":"4243_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/BOR.0b013e328335ef38","volume":"22","author":"HK Choi","year":"2010","unstructured":"Choi HK (2010) A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol 22:165\u2013172","journal-title":"Curr Opin Rheumatol"},{"key":"4243_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.rdc.2014.01.001","volume":"40","author":"E Roddy","year":"2014","unstructured":"Roddy E, Choi HK (2014) Epidemiology of gout. Rheum Dis Clin N Am 40:155\u2013175","journal-title":"Rheum Dis Clin N Am"},{"key":"4243_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13075-016-1062-6","volume":"18","author":"M Dehlin","year":"2016","unstructured":"Dehlin M, Drivelegka P, Sigurdardottir V, Svard A, Jacobsson LT (2016) Incidence and prevalence of gout in Western Sweden. Arthritis Res Ther 18:164","journal-title":"Arthritis Res Ther"},{"key":"4243_CR15","doi-asserted-by":"publisher","first-page":"822","DOI":"10.3899\/jrheum.080768","volume":"36","author":"JG Hanly","year":"2009","unstructured":"Hanly JG, Skedgel C, Sketris I, Cooke C, Linehan T, Thompson K et al (2009) Gout in the elderly\u2014a population health study. J Rheumatol 36:822\u2013830","journal-title":"J Rheumatol"},{"key":"4243_CR16","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMcp1001124","volume":"364","author":"T Neogi","year":"2011","unstructured":"Neogi T (2011) Clinical practice. Gout N Engl J Med 364:443\u2013452","journal-title":"Gout N Engl J Med"},{"key":"4243_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.7326\/M14-0227","volume":"161","author":"E Jutkowitz","year":"2014","unstructured":"Jutkowitz E, Choi HK, Pizzi LT, Kuntz KM (2014) Cost-effectiveness of allopurinol and febuxostat for the management of gout. Ann Intern Med 161:617\u2013626","journal-title":"Ann Intern Med"},{"key":"4243_CR18","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acr.21649","volume":"64","author":"J Anderson","year":"2012","unstructured":"Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, Saag KG, O'dell JR, Kazi S (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 64:640\u2013647","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4243_CR19","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/art.30129","volume":"63","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landew\u00e9 R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M, American College of Rheumatology, European League Against Rheumatism (2011) American College of Rheumatology\/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63:573\u2013586","journal-title":"Arthritis Rheum"},{"key":"4243_CR20","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2013-204798","volume":"74","author":"LH Tuyl van","year":"2015","unstructured":"van Tuyl LH, Hewlett S, Sadlonova M, Davis B, Flurey C, Hoogland W et al (2015) The patient perspective on remission in rheumatoid arthritis: \u2018You've got limits, but you're back to being you again\u2019. Ann Rheum Dis 74:1004\u20131010","journal-title":"Ann Rheum Dis"},{"key":"4243_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrrheum.2017.139","volume":"13","author":"LHD Tuyl van","year":"2017","unstructured":"van Tuyl LHD, Boers M (2017) Rheumatoid arthritis: remission\u2014keeping the patient experience front and Centre. Nat Rev Rheumatol 13:573\u2013574","journal-title":"Nat Rev Rheumatol"},{"key":"4243_CR22","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.3899\/jrheum.161111","volume":"44","author":"LA Rasch","year":"2017","unstructured":"Rasch LA, Boers M, Hill CL, Voshaar M, Hoogland W, de Wit M, Flurey C, Davis B, Hetland ML, Brahe CH, Gossec L, Wells GA, Tugwell P, Kuriya B, Goel N, Singh JA, Duarte C, da Silva J, van Schaardenburg D, Proudman S, van Tuyl L, Working Group on the Patients\u2019 Perspective on Remission in Rheumatoid Arthritis (2017) Validating rheumatoid arthritis remission using the Patients' perspective: results from a special interest group at OMERACT 2016. J Rheumatol 44:1889\u20131893","journal-title":"J Rheumatol"},{"key":"4243_CR23","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/acr.22741","volume":"68","author":"H Lautour de","year":"2016","unstructured":"de Lautour H, Taylor WJ, Adebajo A, Alten R, Burgos-Vargas R, Chapman P, Cimmino MA, da Rocha Castelar Pinheiro G, Day R, Harrold LR, Helliwell P, Janssen M, Kerr G, Kavanaugh A, Khanna D, Khanna PP, Lin C, Louthrenoo W, McCarthy G, Vazquez-Mellado J, Mikuls TR, Neogi T, Ogdie A, Perez-Ruiz F, Schlesinger N, Ralph Schumacher H, Scir\u00e8 CA, Singh JA, Sivera F, Slot O, Stamp LK, Tausche AK, Terkeltaub R, Uhlig T, van de Laar M, White D, Yamanaka H, Zeng X, Dalbeth N (2016) Development of preliminary remission criteria for gout using Delphi and 1000Minds consensus exercises. Arthritis Care Res (Hoboken) 68:667\u2013672","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4243_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.7326\/M16-0570","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem A, Harris RP, Forciea MA, Clinical Guidelines Committee of the American College of P (2017) Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med 166:58\u201368","journal-title":"Ann Intern Med"},{"key":"4243_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.evalprogplan.2009.11.002","volume":"33","author":"WK Jefferson","year":"2010","unstructured":"Jefferson WK, Zunker C, Feucht JC, Fitzpatrick SL, Greene LF, Shewchuk RM, Baskin ML, Walton NW, Phillips B, Ard JD (2010) Use of the nominal group technique (NGT) to understand the perceptions of the healthiness of foods associated with African Americans. Eval Program Plann 33:343\u2013348","journal-title":"Eval Program Plann"},{"key":"4243_CR26","first-page":"974964","volume":"2013","author":"G Kleiner-Fisman","year":"2013","unstructured":"Kleiner-Fisman G, Gryfe P, Naglie G (2013) A patient-based needs assessment for living well with Parkinson disease: implementation via nominal group technique. Parkinsons Dis 2013:974964","journal-title":"Parkinsons Dis"},{"key":"4243_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/146642409611600303","volume":"116","author":"M MacLachlan","year":"1996","unstructured":"MacLachlan M (1996) Identifying problems in community health promotion: an illustration of the nominal group technique in AIDS education. J R Soc Health 116:143\u2013148","journal-title":"J R Soc Health"},{"key":"4243_CR28","doi-asserted-by":"publisher","first-page":"305\u201310","DOI":"10.1177\/014572170002600211","volume":"26","author":"D Miller","year":"2000","unstructured":"Miller D, Shewchuk R, Elliot TR, Richards S (2000) Nominal group technique: a process for identifying diabetes self-care issues among patients and caregivers. Diabetes Educ 26:305\u201310 12, 14","journal-title":"Diabetes Educ"},{"key":"4243_CR29","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00520-009-0721-4","volume":"18","author":"T Pastrana","year":"2010","unstructured":"Pastrana T, Radbruch L, Nauck F, Hover G, Fegg M, Pestinger M et al (2010) Outcome indicators in palliative care\u2014how to assess quality and success. Focus group and nominal group technique in Germany. Support Care Cancer 18:859\u2013868","journal-title":"Support Care Cancer"},{"key":"4243_CR30","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/jhm.1900","volume":"7","author":"A Pena","year":"2012","unstructured":"Pena A, Estrada CA, Soniat D, Taylor B, Burton M (2012) Nominal group technique: a brainstorming tool for identifying areas to improve pain management in hospitalized patients. J Hosp Med 7:416\u2013420","journal-title":"J Hosp Med"},{"key":"4243_CR31","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1467-842X.1997.tb01695.x","volume":"21","author":"S Redman","year":"1997","unstructured":"Redman S, Carrick S, Cockburn J, Hirst S (1997) Consulting about priorities for the NHMRC National Breast Cancer Centre: how good is the nominal group technique. Aust N Z J Public Health 21:250\u2013256","journal-title":"Aust N Z J Public Health"},{"key":"4243_CR32","doi-asserted-by":"publisher","first-page":"R132","DOI":"10.1186\/ar4589","volume":"16","author":"JA Singh","year":"2014","unstructured":"Singh JA (2014) The impact of gout on patient's lives: a study of African-American and Caucasian men and women with gout. Arthritis Res Ther 16:R132","journal-title":"Arthritis Res Ther"},{"key":"4243_CR33","doi-asserted-by":"publisher","first-page":"R82","DOI":"10.1186\/ar4524","volume":"16","author":"JA Singh","year":"2014","unstructured":"Singh JA (2014) Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study. Arthritis Res Ther 16:R82","journal-title":"Arthritis Res Ther"},{"key":"4243_CR34","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/fampra\/10.1.76","volume":"10","author":"M Gallagher","year":"1993","unstructured":"Gallagher M, Hares T, Spencer J, Bradshaw C, Webb I (1993) The nominal group technique: a research tool for general practice? Fam Pract 10:76\u201381","journal-title":"Fam Pract"},{"key":"4243_CR35","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3109\/08820139.2016.1153651","volume":"45","author":"NG Cavalcanti","year":"2016","unstructured":"Cavalcanti NG, Marques CD, Lins ELTU, Pereira MC, Rego MJ, Duarte AL et al (2016) Cytokine profile in gout: inflammation driven by IL-6 and IL-18? Immunol Investig 45:383\u2013395","journal-title":"Immunol Investig"},{"key":"4243_CR36","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/art.1780291209","volume":"29","author":"JS Bomalaski","year":"1986","unstructured":"Bomalaski JS, Lluberas G, Schumacher HR Jr (1986) Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout. Arthritis Rheum 29:1480\u20131484","journal-title":"Arthritis Rheum"},{"key":"4243_CR37","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/art.1780340203","volume":"34","author":"E Pascual","year":"1991","unstructured":"Pascual E (1991) Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum 34:141\u2013145","journal-title":"Arthritis Rheum"},{"key":"4243_CR38","doi-asserted-by":"publisher","first-page":"756","DOI":"10.7326\/0003-4819-131-10-199911160-00007","volume":"131","author":"E Pascual","year":"1999","unstructured":"Pascual E, Batlle-Gualda E, Martinez A, Rosas J, Vela P (1999) Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med 131:756\u2013759","journal-title":"Ann Intern Med"},{"key":"4243_CR39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/art.20405","volume":"51","author":"A Shoji","year":"2004","unstructured":"Shoji A, Yamanaka H, Kamatani N (2004) A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 51:321\u2013325","journal-title":"Arthritis Rheum"},{"key":"4243_CR40","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1136\/ard.2006.060368","volume":"66","author":"E Pascual","year":"2007","unstructured":"Pascual E, Sivera F (2007) Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 66:1056\u20131058","journal-title":"Ann Rheum Dis"},{"key":"4243_CR41","doi-asserted-by":"crossref","unstructured":"Beard SM, von Scheele BG, Nuki G, Pearson IV (2014) Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ 15:453\u201363","DOI":"10.1007\/s10198-014-0617-1"},{"key":"4243_CR42","first-page":"908","volume":"22","author":"MB Ferraz","year":"1995","unstructured":"Ferraz MB, O'Brien B (1995) A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 22:908\u2013914","journal-title":"J Rheumatol"},{"key":"4243_CR43","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, CANTOS Trial Group (2017) Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med 377:1119\u20131131","journal-title":"N Engl J Med"},{"key":"4243_CR44","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/acr.22785","volume":"68","author":"BW Coburn","year":"2016","unstructured":"Coburn BW, Bendlin KA, Sayles H, Hentzen KS, Hrdy MM, Mikuls TR (2016) Target serum urate: do gout patients know their goal? Arthritis Care Res (Hoboken) 68:1028\u20131035","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4243_CR45","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/1742395310378761","volume":"6","author":"LR Harrold","year":"2010","unstructured":"Harrold LR, Mazor KM, Velten S, Ockene IS, Yood RA (2010) Patients and providers view gout differently: a qualitative study. Chronic Illn 6:263\u2013271","journal-title":"Chronic Illn"},{"key":"4243_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/RHU.0b013e318204a8f9","volume":"17","author":"K Lindsay","year":"2011","unstructured":"Lindsay K, Gow P, Vanderpyl J, Logo P, Dalbeth N (2011) The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach. J Clin Rheumatol 17:1\u20136","journal-title":"J Clin Rheumatol"},{"key":"4243_CR47","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/annrheumdis-2011-200801","volume":"71","author":"K Spencer","year":"2012","unstructured":"Spencer K, Carr A, Doherty M (2012) Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis 71:1490\u20131495","journal-title":"Ann Rheum Dis"},{"key":"4243_CR48","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3899\/jrheum.071229","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker MA, Schumacher HR, Benjamin KL, Gorevic P, Greenwald M, Fessel J et al (2009) Quality of life and disability in patients with treatment-failure gout. J Rheumatol 36:1041\u20131048","journal-title":"J Rheumatol"},{"key":"4243_CR49","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3899\/jrheum.111375","volume":"39","author":"V Strand","year":"2012","unstructured":"Strand V, Khanna D, Singh JA, Forsythe A, Edwards NL (2012) Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. J Rheumatol 39:1450\u20131457","journal-title":"J Rheumatol"},{"key":"4243_CR50","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","volume":"72","author":"F Rees","year":"2013","unstructured":"Rees F, Jenkins W, Doherty M (2013) Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 72:826\u2013830","journal-title":"Ann Rheum Dis"},{"key":"4243_CR51","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1136\/ard.2006.055251","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liot\u00e9 F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Piment\u00e3o J, Punzi L, Roddy E, Uhlig T, Zimmermann-G\u00f2rska I, EULAR Standing Committee for International Clinical Studies Including Therapeutics (2006) EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1301\u20131311","journal-title":"Ann Rheum Dis"},{"key":"4243_CR52","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liot\u00e9 F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R, American College of Rheumatology (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64:1431\u20131446","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4243_CR53","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s10067-013-2168-8","volume":"32","author":"PC Robinson","year":"2013","unstructured":"Robinson PC, Schumacher HR Jr (2013) A qualitative and quantitative analysis of the characteristics of gout patient education resources. Clin Rheumatol 32:771\u2013778","journal-title":"Clin Rheumatol"},{"key":"4243_CR54","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/art.40381","volume":"70","author":"AL Gaffo","year":"2018","unstructured":"Gaffo AL, Dalbeth N, Saag KG, Singh JA, Rahn EJ, Mudano AS, Chen YH, Lin CT, Bourke S, Louthrenoo W, Vazquez-Mellado J, Hern\u00e1ndez-Llinas H, Neogi T, Vargas-Santos AB, da Rocha Castelar-Pinheiro G, Amorim RBC, Uhlig T, Hammer HB, Eliseev M, Perez-Ruiz F, Cavagna L, McCarthy GM, Stamp LK, Gerritsen M, Fana V, Sivera F, Taylor W (2018) Brief report: validation of a definition of flare in patients with established gout. Arthritis Rheumatol 70:462\u2013467","journal-title":"Arthritis Rheumatol"},{"key":"4243_CR55","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/art.33483","volume":"64","author":"AL Gaffo","year":"2012","unstructured":"Gaffo AL, Schumacher HR, Saag KG, Taylor WJ, Dinnella J, Outman R, Chen L, Dalbeth N, Sivera F, V\u00e1zquez-Mellado J, Chou CT, Zeng X, Perez-Ruiz F, Kowalski SC, Goldenstein-Schainberg C, Chen L, Bardin T, Singh JA (2012) Developing a provisional definition of flare in patients with established gout. Arthritis Rheum 64:1508\u20131517","journal-title":"Arthritis Rheum"},{"key":"4243_CR56","unstructured":"NIH (2016) Gout: Allopurinol vs. Febuxostat. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02579096\n                    \n                  . Bethesda, Maryland: \n                    Clinicaltrials.gov\n                    \n                  . A service of the U.S. National Institutes of Health"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4243-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4243-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4243-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,3]],"date-time":"2019-08-03T19:13:21Z","timestamp":1564859601000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4243-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,4]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["4243"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4243-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2018,8,4]]},"assertion":[{"value":"11 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JAS has received research grants from Takeda and Savient pharmaceuticals and consultant fees from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta\/Horizon and Allergan pharmaceuticals, WebMD, UBM LLC, Medscape, Fidia pharmaceuticals, and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc., a 501 (c) (3) entity. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology\u2019s (ACR) Annual Meeting Planning Committee (AMPC); Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The University of Alabama at Birmingham\u2019s Institutional Review Board approved this study (X120404005), and all investigations were conducted in conformity with ethical principles of research. All patients involved in the study including consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\/IRB approval and consent to participate"}}]}}